As per our research report, the global sepsis diagnostics market size was worth USD 1014 million in 2021 and is estimated to be growing at a CAGR of 8.51% to reach USD 1525 million by 2026. The increasing prevalence of the disease and its fatal effects have stimulated its growth.
Sepsis is defined as the body’s reaction to the bacteria, fungal, viral, or plastic infection, leading to the systemic inflammatory response, organ failure, or organ dysfunction. Sepsis is emerging as a leading cause of mortality around the globe. The market players are focussing on launching advanced technological products to ensure sepsis diagnosis at the initial stages. Moreover, companies enter mergers and acquisitions to operate research and development activities and expand nationwide market growth.
As per the reports, some products have already been introduced in the United States in food and drug administration for diagnosis purposes. According to the Centers for disease control and prevention, it is estimated that 1.7 million people suffer from hospital-acquired infections (HAI) every year in the United States. As per the ECDC, 2013, around 4.1 million patients were diagnosed with HAI in Europe. However, developed countries equipped with advanced facilities and fewer sepsis cases have been recorded in the study of more than 7000 patient outcomes using the Early Sense systems. The number of ICU days for transferred cases has decreased by 46%.
MARKET DRIVERS:
The growth of the global sepsis diagnostic market is anticipated to be driven by factors such as the growing burden of infectious diseases and an increasing number of sepsis incidences globally. According to thelancet.com, An estimated 48.9 million sepsis cases were identified in 2017, in which 11.0 sepsis-related deaths were recorded. People with weak immune systems and people with chronic diseases such as diabetes, cancer, and AIDS are vulnerable to contracting sepsis, which is expected to drive market growth.
However, the increasing prevalence of antibiotic-resistant bacterial strains and rising concern about the health of the people worldwide, and growing healthcare expenditure is projected to improve the market growth. Majorly, government incentives and investment expenditure to improve the healthcare expenditure propel the Sepsis Diagnostics Market during the forecast period.
MARKET RESTRAINTS:
However, lack of standard protocol for sepsis and unavailability of professionals in developing countries are major challenging factors for the global sepsis diagnostics market growth.
Impact of COVID-19 on the global sepsis diagnostics market:
The outbreak of COVID-19 has increased the overall risk of sepsis among the population. As per the global alliance, it is stated that COVID-19 can cause sepsis. The COVID-19 infected patient's body gets overwhelmed, and a life-threatening response can lead to organ damage and lead to death. As per reports, one in three COVID-19 patients dies in the hospital because of sepsis in the United States. With the high vulnerability of the disease in this region, the market is projected to have better growth in the coming years.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Pathogen, Product, Technology, Method, Usability, End-User, Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
This market research report on the global sepsis diagnostics market has been segmented and sub-segmented based on the pathogen, product, technology, method, usability, end-user, and region.
Sepsis Diagnostics Market Analysis – By Pathogen:
Based on the pathogen, the bacterial sepsis segment is forecasted to register the leading market share during the forecast period in the global sepsis diagnostics market. Based on the fact that most patients suffering from blood poisoning disease are patients of bacterial infection, the bacterial sepsis segment held the most significant share in 2019. Gram-negative bacteria are the most frequent bacterial sepsis. The gram-positive bacterial sepsis segment is anticipated to dominate the market during the forecast period. Extensive research and development activities and favorable regulatory approval of novel solutions are expected to support the segment growth.
Due to the rise of Candida infection resulting in septic poisoning, fungal sepsis is to expand at an appealing CAGR. This disease comes from a smaller number of viruses and parasites, so this segment accounted for a minimal share in 2020.
Sepsis Diagnostics Market Analysis – By Product:
Based on product, Blood culture media was estimated to be the largest grossing segment in 2020. It grows more rapidly over the forecast period because physicians know blood culture as the gold standard form and cost-effective method of screening. The blood culture media is considered as the cost-effective and standard method by most clinicians.
The assay kits and reagents segment will show lucrative growth due to their new diagnostic capability and the implementation of automated testing by significant companies.
Sepsis Diagnostics Market Analysis – By Technology:
Sepsis Diagnostics Market Analysis – By Method:
Sepsis Diagnostics Market Analysis – By Usability:
Sepsis Diagnostics Market Analysis – By Region:
Regionally, the North American sepsis diagnostics market recorded the largest share in terms of revenue in the global market in 2019, and it is expected to increase its dominance during the forecast period. With an increase in healthcare expenditure, rapid adoption of advanced diagnostic products in the United States is expected to drive this regional market. Favorable reimbursement scenarios for diagnostic tests in the United States and active participation of key market players are projected to grow.
The European sepsis diagnostics market is projected to grow at a significant rate between 2020 to 2025. The European market held the second-largest share concerning revenue in the global market in 2019. High incidence of healthcare expenditure and advanced medical procedures are augmenting market growth over the years.
The Asia Pacific sepsis diagnostics market is the quickest growing region globally and is predicted to grow at a healthy rate between 2020 to 2025. Improving healthcare infrastructure facilities and the availability of advanced diagnostic products and favorable government initiatives, and the rise in healthcare expenditure influence market growth in this region.
The sepsis diagnostics market in the Middle East & Africa region was accounted for a small share in the global market in 2019 due to the growing burden of infectious diseases. It is further projected to grow at a steady rate from 2020 to 2025. The increasing number of sepsis incidences in this region and raising awareness among healthcare people augment market growth.
KEY MARKET PARTICIPANTS AND SHARE INSIGHTS:
Some of the notable companies dominating the global sepsis diagnostics market profiled in this report are BioMérieux SA, T2 Biosystems Inc., Cepheid, Thermo Fisher Scientific Inc., Nanosphere Inc., Abbott Laboratories, Roche Diagnostics Limited, Becton Dickinson and Company, Bruker Corporation, and Beckman Coulter, Inc.
In April 2018, Curetis NV collaborated with partner Acumen Research Laboratories Pte. Ltd received approval for Unyvero BCU Cartridge for bloodstream infections in Singapore.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Pathogen
5.1.1 Introduction
5.1.2 Bacterial Sepsis
5.1.2.1 Gram-Negative Bacterial Sepsis
5.1.2.2 Gram-Positive Bacterial Sepsis
5.1.3 Fungal Sepsis
5.1.4 Other Pathogen Infections
5.1.5 Y-o-Y Growth Analysis, By Pathogen
5.1.6 Market Attractiveness Analysis, By Pathogen
5.1.7 Market Share Analysis, By Pathogen
5.2 Product
5.2.1 Introduction
5.2.2 Instruments
5.2.3 Blood Culture Media
5.2.4 Assay Kits & Reagents
5.2.5 Software
5.2.6 Y-o-Y Growth Analysis, By Product
5.2.7 Market Attractiveness Analysis, By Product
5.2.8 Market Share Analysis, By Product
5.3 Technology
5.3.1 Introduction
5.3.2 Microbiology
5.3.3 Molecular Diagnostics
5.3.4 Immunoassays
5.3.5 Flow Cytometry
5.3.6 Other Technologies
5.3.7 Y-o-Y Growth Analysis, By Technology
5.3.8 Market Attractiveness Analysis, By Technology
5.3.9 Market Share Analysis, By Technology
5.4 Method
5.4.1 Introduction
5.4.2 Convential Diagnostics
5.4.3 Automated Diagnostics
5.4.4 Y-o-Y Growth Analysis, By Method
5.4.5 Market Attractiveness Analysis, By Method
5.4.6 Market Share Analysis, By Method
5.5 Usability
5.5.1 Introduction
5.5.2 Laboratory Testing
5.5.3 Point-of-Care Testing
5.5.4 Y-o-Y Growth Analysis, By Usability
5.5.5 Market Attractiveness Analysis, By Usability
5.5.6 Market Share Analysis, By Usability
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Pathogen
6.1.3.3 By Product
6.1.3.4 By Technology
6.1.3.5 By Method
6.1.3.6 By Usability
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Pathogen
6.1.4.3 By Product
6.1.4.4 By Technology
6.1.4.5 By Method
6.1.4.6 By Usability
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Pathogen
6.1.5.3 By Product
6.1.5.4 By Technology
6.1.5.5 By Method
6.1.5.6 By Usability
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 bioMérieux SA
8.1.1 Overview
8.1.2 Pathogen Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 T2 Biosystem Inc
8.3 Cepheid
8.4 Thermo Fisher Scientific Inc.
8.5 Nanosphere Inc
8.6 Abbott Laboratories
8.7 Roche Diagnostics Limited
8.8 Becton, Dickinson and Company
8.9 Bruker Corporation
8.10 Beckman Coulter, Inc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
